NICE technology appraisal guidance
Issued: January 2012
TA244
Roflumilast for the management of severe chronic obstructive pulmonary disease
This is an extract from the guidance. The complete guidance is available at guidance.nice.org.uk/ta244
6 Recommendations for further research
6.1 Nycomed is conducting a 52-week, randomised, double-blind study (REACT) to assess the effect of roflumilast on exacerbation rates when added to LABA/ICS.
6.2 The Committee recommends that a study is conducted to generate robust evidence about the benefits of roflumilast as an add-on to LAMA plus LABA/ICS or LAMA plus LABA for those people who are intolerant to ICS.
6.3 Ideally roflumilast should be compared with theophylline in those people for whom theophylline would be suitable.